Patents by Inventor Eisaku Yoshida

Eisaku Yoshida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of diagnosing hepatocellular carcinoma and pancreatic cancer
    Patent number: 11340229
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 24, 2022
    Assignees: Abbott Japan LLC, The University of Tokyo
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • METHODS OF DIAGNOSING HEPATOCELLULAR CARCINOMA AND PANCREATIC CANCER
    Publication number: 20190242899
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 8, 2019
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • Immunoassay methods and reagents for decreasing nonspecific binding
    Patent number: 10107826
    Abstract: Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl2, MgCl2, and a sulfobetaine zwitterionic detergent.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 23, 2018
    Assignee: Abbott Japan Co. Ltd.
    Inventors: Toru Yoshimura, Eisaku Yoshida, Ryotaro Chiba
  • METHODS OF DIAGNOSING HEPATOCELLULAR CARCINOMA AND PANCREATIC CANCER
    Publication number: 20170089905
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 30, 2017
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • Antibodies relating to PIVKA-II and uses thereof
    Patent number: 9120862
    Abstract: The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: September 1, 2015
    Assignees: ABBOTT LABORATORIES, ABBOTT JAPAN
    Inventors: Toru Yoshimura, Barry Lee Dowell, Gangamani S. Beligere, Eisaku Yoshida
  • METHODS OF PROGNOSIS AND DIAGNOSIS OF CANCER
    Publication number: 20140045196
    Abstract: Provided are methods of diagnosing cancer in a patient by detecting the presence and/or amount of a biomarker of cancer in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having cancer or suspected of having cancer, or to accurately diagnose a patient having, or suspected of having cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a cancer therapy.
    Type: Application
    Filed: August 8, 2013
    Publication date: February 13, 2014
    Applicants: University of Tokyo, Abbott Japan Co., Ltd
    Inventors: Noahiko Koshikawa, Masatoshi Nakagawa, Eisaku Yoshida, Toru Yoshimura, Motoharu Seiki
  • IMMUNOASSAY METHODS AND REAGENTS FOR DECREASING NONSPECIFIC BINDING
    Publication number: 20130130275
    Abstract: Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl2, MgCl2, and a sulfobetaine zwitterionic detergent.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 23, 2013
    Applicant: ABBOTT JAPAN CO., LTD.
    Inventors: Toru Yoshimura, Eisaku Yoshida, Ryotaro Chiba
  • ANTIBODIES RELATING TO PIVKA-II AND USES THEREOF
    Publication number: 20120020972
    Abstract: The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.
    Type: Application
    Filed: July 26, 2010
    Publication date: January 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Toru Yoshimura, Barry Lee Dowell, Gangamani S. Beligere, Eisaku Yoshida
  • Novel peptides possessing a macrophage chemotactic activity
    Patent number: 5097013
    Abstract: The present invention relates to physiologically active peptides and more particularly, to novel peptides having a specific amino acid sequence which possess a macrophage chemotactic activity.
    Type: Grant
    Filed: July 12, 1989
    Date of Patent: March 17, 1992
    Assignee: Kao Corporation
    Inventors: Toshiaki Osawa, Naonobu Yoshizuka, Masaaki Yoshimura, Eisaku Yoshida